THERAPEUTIC CLASS

Immune checkpoint therapy for non-smallcell lung cancer: an update

---

The role of immunotherapy in treatment of non-small-cell lung cancer (NSCLC)
has been gaining interest over the past few years. This has been driven primarily
by promising results from trials evaluating antagonist antibodies that target coinhibitory
immune checkpoints expressed on tumor cells and immune cells within the
tumor microenvironment. Immune checkpoints exist to dampen or terminate immune
activity to guard against autoimmunity and allow for self-tolerance

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Oncology
Fonkopac
Carboplatin
Epirubicin
Biobran

Specific Detail Info

-

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment